Barclays Has Lowered Expectations for CVS Health (NYSE:CVS) Stock Price

07 Nov 2026, 16:54 by Kim Johansen · The Markets Daily

CVS Health (NYSE:CVS – Get Free Report) had its target price decreased by analysts at Barclays from $108.00 to $107.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage presently has an “overweight” rating on the pharmacy operator’s stock. Barclays‘s price objective would suggest a potential upside of 27.75% from the stock’s current price.

Several other research firms have also recently commented on CVS. Cantor Fitzgerald reissued a “neutral” rating on shares of CVS Health in a research note on Friday, October 9th. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a research note on Thursday, August 6th. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $112.00 price target on shares of CVS Health in a research note on Wednesday, September 9th. JPMorgan Chase & Co. lifted their price target on CVS Health from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings downgraded CVS Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, October 9th. Twenty-two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $108.25.

Check Out Our Latest Analysis on CVS

CVS Health Stock Performance

CVS Health stock traded up $2.43 during midday trading on Thursday, reaching $83.76. 16,092,787 shares of the stock traded hands, compared to its average volume of 8,249,097. CVS Health has a fifty-two week low of $69.51 and a fifty-two week high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market cap of $107.12 billion, a price-to-earnings ratio of 9.75, a PEG ratio of 0.82 and a beta of 0.58. The firm has a fifty day moving average price of $90.37 and a two-hundred day moving average price of $88.89.

CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The pharmacy operator reported $2.09 EPS for the quarter, beating the consensus estimate of $1.65 by $0.44. The company had revenue of $108.40 billion for the quarter, compared to analyst estimates of $104.72 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business earned $1.60 earnings per share. On average, equities research analysts forecast that CVS Health will post 8.26 earnings per share for the current year.

Insider Activity at CVS Health

In other CVS Health news, EVP Prem Shah bought 23,855 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The shares were acquired at an average cost of $83.89 per share, for a total transaction of $2,001,195.95. Following the acquisition, the executive vice president directly owned 88,516 shares of the company’s stock, valued at $7,425,607.24. This trade represents a 36.89% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.85% of the stock is owned by insiders.

Institutional Trading of CVS Health

A number of large investors have recently added to or reduced their stakes in the business. Kilter Group LLC bought a new position in shares of CVS Health in the second quarter valued at $27,000. Beaird Harris Wealth Management LLC lifted its position in shares of CVS Health by 201.0% during the 2nd quarter. Beaird Harris Wealth Management LLC now owns 292 shares of the pharmacy operator’s stock valued at $30,000 after acquiring an additional 195 shares during the last quarter. J.Safra Asset Management Corp bought a new stake in shares of CVS Health during the 2nd quarter worth $30,000. Timbuktu Capital Management LLC acquired a new position in shares of CVS Health in the 2nd quarter worth $31,000. Finally, Dunhill Financial LLC acquired a new position in shares of CVS Health in the 2nd quarter worth $32,000. 80.66% of the stock is currently owned by institutional investors.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

Positive Sentiment: Executive Vice President Prem Shah bought 23,855 shares for about $2 million, increasing his direct stake by 36.9%. The sizable purchase may signal confidence in CVS’s prospects. SEC filing
Positive Sentiment: CVS beat third-quarter earnings and revenue estimates and raised its 2026 outlook, with Aetna’s recovery among the factors supporting the improved outlook. Q3 earnings call coverage
Neutral Sentiment: UBS lowered its price target to $107 but maintained a Buy rating, indicating continued optimism while reflecting a more cautious valuation. UBS rating
Negative Sentiment: The planned separation of the retail pharmacy business from the insurance and pharmacy-benefit operations by 2028 has raised questions about execution, costs, and the value of the two businesses. The announcement overshadowed the earnings beat and was followed by a sharp selloff. Breakup and stock reaction
Negative Sentiment: Additional concerns include weaker Medicare ratings and AM Best placing ratings for Aetna subsidiaries under review, creating uncertainty around the insurance business. Medicare ratings coverage

CVS Health Company Profile

(Get Free Report)

CVS Health is a U.S.-based health care company that operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance and other health services. Its businesses include CVS Pharmacy, pharmacy benefit manager CVS Caremark, and Aetna, its health benefits division.

The company also provides care through MinuteClinic walk-in clinics and health care businesses including Oak Street Health and Signify Health. Its services span prescription fulfillment, pharmacy benefit management, health insurance, primary care, and in-home and community-based care.